Our survey focused exclusively on medical oncology and infusion costs, which may differ according to a variety of factors including a patient’s tumor size, hormone receptor and Her2/neu status, tumor gene expression status, whether the patient is pre- or post-menopausal, as well as individual patient variability [19]. This evidence concerns the gene ERBB2 and neoplasm.